Orbis Research

Orbisresearch.com added latest 365 pages report “PharmaPoint: Human Immunodeficiency Virus (HIV)-Global Drug Forecast and Market Analysis to 2025” in its store.

DALLAS, TEXAS, UNITED STATES, August 29, 2017 /EINPresswire.com/ -- Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline’s (GSK’s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience.

Companies Mentioned:
Gilead Sciences
ViiV Healthcare
Janssen
Merck & Co.
Bristol-Myers Squibb
TaiMed Biologics
CytoDyn

Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/358341

GlobalData projects the global HIV marketplace - which, for the purposes of this report, comprises nine major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) - to experience modest growth during the forecast period. This growth will be driven primarily by the highly anticipated arrivals of novel integrase inhibitor (INI-) and protease inhibitor (PI-) based STRs, which include ViiV Healthcare’s dolutegravir/lamivudine, ViiV’s and Janssen’s dolutegravir/rilpivirine, Gilead’s bictegravir/emtricitabine/tenofovir alafenamide fumarate (TAF), Gilead’s and Janssen’s darunavir/cobicistat/emtricitabine/TAF, and ViiV’s long-acting injectable formulation composed of cabotegravir/rilpivirine. Nevertheless, looming patent expiries of high-grossing branded drugs in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with compulsory licensing and generic erosion in Brazil and China, are expected to curtail market growth.

Key Questions Answered
- How will the HIV market landscape in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) change from 2015-2025?
- What are the most promising late-stage pipeline drugs in HIV?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
- What are the remaining unmet needs in HIV treatment management?
- What drivers and barriers will affect HIV therapeutics sales in the 9MM over the forecast period?

Scope
- Overview of HIV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline HIV market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting HIV therapeutics sales in the 9MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global HIV therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HIV therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HIV therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Buy a report @ http://www.orbisresearch.com/contact/purchase/358341

List of Figures
Figure 1: Global Sales for HIV by Country/Region, 2015 and 2025 14
Figure 2: Company Portfolio Gap Analysis in HIV, 2015-2025 15
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in HIV, 2015-2025 20
Figure 4: Cartoon Depicting the HIV Lifecycle 26
Figure 5: Global Overview of HIV, Men and Women, All Ages, 1990-2015 38
Figure 6: 8MM, Total Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015-2025 67
Figure 7: 8MM, Diagnosed Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015-2025 69
Figure 8: 8MM, Age-Specific Diagnosed Prevalent Cases of HIV, Both Sexes, N, Select Years, 2015-2025 71
Figure 9: 8MM, Sex-Specific Diagnosed Prevalent Cases of HIV, All Ages, N, Select Years, 2015-2025 73
Figure 10: 8MM, Age-Standardized Diagnosed Prevalence of HIV (%), All Ages, by Sex, 2015 74
Figure 11: Japan, 20-Year Diagnosed Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015-2025 78
Figure 12: Japan, Age-Standardized 20-Year Diagnosed Prevalence of HIV (%), All Ages, by Sex, 2015 80
Figure 13: HIV Disease Management Flowchart 88
Figure 14: HIV - Phase III Pipeline, 2016 205
Figure 15: Competitive Assessment of Late-Stage Pipeline Agents in HIV, 2015-2025 206
Figure 16: Company Portfolio Gap Analysis in HIV, 2015-2025 250
Figure 17: Global Sales for HIV by Country/Region, 2015 and 2025 273
Figure 18: Global Sales for HIV by Drug Class, 2015 and 2025 274
Figure 19: Sales for HIV by Drug Class in the US, 2015 and 2025 280
Figure 20: Sales for HIV by Drug Class in the 5EU, 2015 and 2025 288
Figure 21: Sales for HIV by Drug Class in Japan, 2015 and 2025 294
Figure 22: Sales for HIV by Drug Class in Brazil, 2015 and 2025 299
Figure 23: Sales for HIV by Drug Class in China, 2015 and 2025 304

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Hector Costello
Orbis Research
+1 (214) 884-6817
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.